Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have received a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $35.25.

Several analysts have issued reports on the company. Wedbush increased their target price on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Robert W. Baird dropped their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday. JonesTrading dropped their target price on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Alto Neuroscience in a research report on Monday, May 11th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday, April 22nd.

Alto Neuroscience Trading Down 6.7%

ANRO opened at $20.33 on Wednesday. The stock’s fifty day moving average is $23.25 and its two-hundred day moving average is $18.64. The company has a market capitalization of $713.52 million, a P/E ratio of -8.40 and a beta of 1.62. Alto Neuroscience has a 52 week low of $2.15 and a 52 week high of $28.44. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Analysts forecast that Alto Neuroscience will post -2.86 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its position in Alto Neuroscience by 131.5% during the 1st quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock valued at $577,000 after acquiring an additional 14,585 shares in the last quarter. Eversept Partners LP acquired a new stake in shares of Alto Neuroscience in the 1st quarter worth $2,814,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Alto Neuroscience in the 1st quarter worth $534,000. Quantinno Capital Management LP boosted its position in shares of Alto Neuroscience by 1.4% in the 1st quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock worth $811,000 after purchasing an additional 490 shares in the last quarter. Finally, Orbimed Advisors LLC boosted its position in shares of Alto Neuroscience by 34.0% in the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock worth $3,765,000 after purchasing an additional 42,500 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.